NinePointTwo Capital’s Arcus Biosciences RCUS Stock Holding History

NinePointTwo Capital’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-15,916	Closed	-$290K	–	316
2023 Q1	$290K	Buy	+15,916	New	+$304K	0.11%	50
2022 Q4	–	Sell	-8,732	Closed	-$228K	–	245
2022 Q3	$228K	Sell	8,732 -8,704	-50%	-$230K	0.09%	144
2022 Q2	$441K	Buy	+17,436	New	+$427K	0.15%	43

Other funds holding RCUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

NinePointTwo Capital's RCUS Position: Q2 2023 in Review

NinePointTwo Capital sold out of Arcus Biosciences (RCUS) in Q2 2023, closing a stake of 15,916 shares — an estimated $290K sold.

NinePointTwo Capital first reported a position in RCUS in Q2 2022 and held it in 3 quarters. The position peaked at $441K in Q2 2022. 181 funds tracked by Wall St. Rank hold RCUS as of Q2 2023.

NinePointTwo Capital reported no remaining Arcus Biosciences position as of Q2 2023 after selling out during the quarter.
NinePointTwo Capital sold 15,916 Arcus Biosciences shares in Q2 2023, an estimated $290K.
NinePointTwo Capital first reported a position in Arcus Biosciences in Q2 2022 and held it in 3 quarters.
NinePointTwo Capital's Arcus Biosciences position peaked at $441K in Q2 2022.
181 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2023.

Based on NinePointTwo Capital's 13F filing for Q2 2023, filed 14 Aug 2023.